HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.0%

Neg 0% Neu 91% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.